---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009977"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T15:01:56.679466+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete

## Summary
- Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.
- Cash, equivalents & short-term investments $101.2M as of Dec 31, 2022.
- R&D expenses $37.7M in 2022, up 34% due to STRIDE and STRIDE AHEAD studies.
- Pivotal STRIDE study (PMM) enrolled target 200 patients; topline results expected Q4 2023.
- Plans to study mavodelpar in PMM due to nDNA defects and advance LC-FAOD program into Phase 2.

## SEC filing metadata
- accession: 0000950170-23-009977
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/0000950170-23-009977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/rphm-20230327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009977
- JSON: https://secwatch.observer/filing/0000950170-23-009977.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009977.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Net income: net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022
  - Result: reported results
  source text: We reported a net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022, compared to a net loss of $10.6 million, or $0.43 per share, for the same period in 2021. For the full year 2022, we reported a net loss of $52.0 million, or $2.12 per share, compared to a net loss of $39.8 million, or $2.19 per share, for the full year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/0000950170-23-009977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.